Risk factors for gastric perforation after cytoreductive surgery in patients with peritoneal carcinomatosis: Splenectomy and increased body mass index.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
10
2020
accepted:
22
02
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Gastric perforation after cytoreductive surgery (CRS) is an infrequent complication. There is lack of evidence regarding the risk factors for this postoperative complication. The aim of this study was to assess the prevalence of postoperative gastric perforation in patients undergoing CRS for peritoneal carcinomatosis (PC) and to evaluate risk factors predisposing to this complication. We designed a unicentric retrospective study to identify all patients who underwent an open upfront or interval CRS after a primary diagnosis of PC of different origins between March 2007 and December 2018 at a French Comprehensive Cancer Center. The main outcome was the occurrence of postoperative gastric perforation. Five hundred thirty-three patients underwent a CRS for PC during the study period and 13 (2.4%) presented a postoperative gastric perforation with a mortality rate of 23% (3/13). Neoadjuvant chemotherapy was administered in 283 (53.1%) patients and 99 (18.6%) received hyperthermic intraperitoneal chemotherapy (HIPEC). In the univariate analysis, body mass index (BMI), peritoneal cancer index, splenectomy, distal pancreatectomy, and histology were significantly associated with postoperative gastric perforation. After multivariate analysis, BMI (OR [95%CI] = 1.13 [1.05-1.22], p = 0.002) and splenectomy (OR [95%CI] = 26.65 [1.39-509.67], p = 0.029) remained significantly related to the primary outcome. Gastric perforation after CRS is a rare event with a high rate of mortality. While splenectomy and increased BMI are risk factors associated with this complication, HIPEC does not seem to be related. Gastric perforation is probably an ischemic complication due to a multifactorial process. Preventive measures such as preservation of the gastroepiploic arcade and prophylactic suture of the greater gastric curvature require further assessment.
Sections du résumé
BACKGROUND
Gastric perforation after cytoreductive surgery (CRS) is an infrequent complication. There is lack of evidence regarding the risk factors for this postoperative complication. The aim of this study was to assess the prevalence of postoperative gastric perforation in patients undergoing CRS for peritoneal carcinomatosis (PC) and to evaluate risk factors predisposing to this complication.
METHODS
We designed a unicentric retrospective study to identify all patients who underwent an open upfront or interval CRS after a primary diagnosis of PC of different origins between March 2007 and December 2018 at a French Comprehensive Cancer Center. The main outcome was the occurrence of postoperative gastric perforation.
RESULTS
Five hundred thirty-three patients underwent a CRS for PC during the study period and 13 (2.4%) presented a postoperative gastric perforation with a mortality rate of 23% (3/13). Neoadjuvant chemotherapy was administered in 283 (53.1%) patients and 99 (18.6%) received hyperthermic intraperitoneal chemotherapy (HIPEC). In the univariate analysis, body mass index (BMI), peritoneal cancer index, splenectomy, distal pancreatectomy, and histology were significantly associated with postoperative gastric perforation. After multivariate analysis, BMI (OR [95%CI] = 1.13 [1.05-1.22], p = 0.002) and splenectomy (OR [95%CI] = 26.65 [1.39-509.67], p = 0.029) remained significantly related to the primary outcome.
CONCLUSIONS
Gastric perforation after CRS is a rare event with a high rate of mortality. While splenectomy and increased BMI are risk factors associated with this complication, HIPEC does not seem to be related. Gastric perforation is probably an ischemic complication due to a multifactorial process. Preventive measures such as preservation of the gastroepiploic arcade and prophylactic suture of the greater gastric curvature require further assessment.
Identifiants
pubmed: 33661999
doi: 10.1371/journal.pone.0248205
pii: PONE-D-20-33398
pmc: PMC7932550
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248205Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Surg Oncol. 2005 Feb;31(1):53-8
pubmed: 15642426
Surg Radiol Anat. 2017 Apr;39(4):433-440
pubmed: 27655148
Cancer. 2006 Mar 1;106(5):1144-53
pubmed: 16456817
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Gynecol Oncol. 2009 Sep;114(3):523-7
pubmed: 19344936
Scand J Gastroenterol. 2013 Feb;48(2):168-75
pubmed: 23215900
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
J Surg Oncol. 1994 Aug;56(4):246-8
pubmed: 8057651
ISRN Obes. 2014 Feb 20;2014:638936
pubmed: 24701367
Cell Mol Life Sci. 2018 Feb;75(3):509-525
pubmed: 28956065
J Surg Oncol. 2010 Jun 1;101(7):634-6
pubmed: 20461773
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Eur J Surg Oncol. 2006 Aug;32(6):597-601
pubmed: 16617003
Gynecol Oncol. 2005 Aug;98(2):235-41
pubmed: 15982725
Eur J Surg Oncol. 2016 Feb;42(2):224-33
pubmed: 26673283
J Surg Oncol. 2015 Mar;111(3):324-7
pubmed: 25557653
N Engl J Med. 1989 Apr 13;320(15):970-3
pubmed: 2927479
Ann Surg Oncol. 2008 Feb;15(2):535-41
pubmed: 17960463
World J Surg Oncol. 2017 Feb 10;15(1):44
pubmed: 28187769
Ann Surg Oncol. 2016 Jun;23(6):1941-7
pubmed: 26842489
J Clin Oncol. 2009 Dec 20;27(36):6237-42
pubmed: 19917862
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
Gynecol Oncol. 2019 Apr;153(1):209-210
pubmed: 30558973
J Clin Oncol. 2003 Mar 1;21(5):799-806
pubmed: 12610177
Int J Gynecol Cancer. 2020 Apr;30(4):556-557
pubmed: 31843870
Gynecol Oncol. 2010 Oct;119(1):38-42
pubmed: 20609464
Int J Gynecol Cancer. 2019 Jan 23;:
pubmed: 30674567
Ann Transl Med. 2017 Jun;5(11):236
pubmed: 28706904